Peptide · Dual GIP and GLP-1 receptor agonist
Tirzepatide
A dual GIP and GLP-1 receptor agonist peptide, authorised as a prescription medicine for type 2 diabetes and weight management.
Approved medicineAuthorised by a regulator, available on prescription.
- Legal status · US
- Approved medicine
- Evidence in people
- Molecule
- Dual GIP and GLP-1 receptor agonist
- In sport
- Not named on the WADA list
- Status checked
Regulatory status · United States
This describes the position in the United States. Rules in Switzerland differ; an approved peptide medicine there is in its national register.
An approved prescription medicine. Its authorised products are in the ordinary catalogue, each with its official label.
Authorised products
| Brand | Authorised for | How it is given | First US approval |
|---|---|---|---|
| Mounjaro | Type 2 diabetes | Injection, once a week | 2022 |
| Zepbound | Weight management; obstructive sleep apnoea with obesity | Injection, once a week | 2023 |
Doses, warnings and who should not use it are on each product’s official label, linked from its page.
Every authorised product in SwitzerlandWhat changed, and when
First US approval, as Mounjaro, for type 2 diabetes.
Approved for chronic weight management, as Zepbound.
Zepbound approved for moderate-to-severe obstructive sleep apnoea in adults with obesity.
What to be careful about
Search interest has produced a large grey market. A vial bought online is not the authorised product and its contents are unverified.
Sources
Regulatory positions change. This page states the date it describes, and nothing on it is legal or medical advice.